Ms. Burow is focused on the creation and development of biotechnology, pharmaceutical and health tech companies. Since joining ARCH in 2002, she has risen from Associate to Managing Director and has played a significant role in the growth of ARCH’s life sciences portfolio, including multiple public companies exceeding billion dollar valuations.
Ms. Burow is a Director of Beam Therapeutics (BEAM), Vividion Therapeutics, RBNC, Gossamer Bio (GOSS), Metacrine (MTCR), Scholar Rock (SRRK), Unity Biotechnology (UBX), Boundless Bio, Autobahn Therapeutics, ROME Therapeutics, Boragen and AgBiome. She previously was a co-founder and Director of Receptos (RCPT – acquired by Celgene) and was a Director of VIR Biotechnology (VIR), Epirium Bio and BlackThorn Therapeutics. Ms. Burow has participated and led investments in a number of other ARCH portfolio companies including Erasca, Dewpoint, Therapeutics, Mindstrong, Aledade, Kura Oncology (KURA), Kythera Biopharmaceuticals (KYTH – acquired by Allergan), and Ikaria (acquired by Mallinckrodt).
Prior to joining ARCH Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spin-outs from GNF.
Ms. Burow holds an M.B.A. from the University of Chicago, an M.A. in Chemistry from Columbia University and a B.S. in Chemistry from the University of California, Berkeley.